Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 8-K (Current Report)
Date of Report: March 3, 2022
Reporting Period: Events occurring on March 3, 2022, and effective March 4, 2022.
Key Financial Metrics
This filing is a current report regarding corporate events and agreements. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Corporate Actions
Item 1.01: Entry into a Material Definitive Agreement
- Agreement: Supply and Development Support Agreement with Musculoskeletal Transplant Foundation, Inc. (MTF).
- Terms: MTF is designated as the exclusive supplier of demineralized bone matrix (DBM) for use with the Company's Nell-1 product.
- Support: MTF will provide reasonable development support for Nell-1 with DBM as a carrier.
- Duration: Five-year term, extendable by mutual agreement.
- Provisions: Includes delivery, inspection, warranties, quality management, compliance, forecasts, IP rights, indemnification, and confidentiality.
Item 5.03: Amendments to Bylaws
Effective March 4, 2022, the Board adopted Amended and Restated Bylaws with the following key changes:
- Special Meetings: Stockholders holding 15% of voting power can now call a Special Meeting (previously limited to directors and officers).
- Stockholder Proposals: New detailed procedures added for stockholder business proposals and director nominations at Annual and Special Meetings.
- Amendment Threshold: Bylaw amendments can now be made by a majority of directors or 2/3 of voting power (previously required unanimous director consent).
- Exclusive Forum: The Delaware Court of Chancery is designated as the exclusive forum for derivative actions, breach of fiduciary duty, and internal affairs doctrine claims (excluding federal securities law claims).
Guidance, Outlook, and Risks
Management Commentary: The Board believes the Bylaw amendments provide greater rights and flexibility to stockholders and assist in attracting qualified directors by preventing forum shopping. The MTF agreement secures a critical supply chain component for the Nell-1 product development.
Risks and Contingencies: The filing does not explicitly detail new risks, though the reliance on an exclusive supplier (MTF) for DBM introduces supply chain concentration risk. The exclusive forum provision limits the venue for certain legal actions.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the full text of the Supply and Development Support Agreement with MTF, which is expected to be filed in the next periodic report.
- Review the Amended and Restated Bylaws (Exhibit 3.1) to understand the specific procedural changes for stockholder proposals and director nominations.
- Confirm the status of the Nell-1 product development and the strategic importance of DBM as a carrier.
- Monitor future filings for financial impact related to the MTF agreement costs or revenue implications.